Which Has More Side Effects: Wegovy or Mounjaro?

Last reviewed: July 9, 2026

Last updated: July 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide (Wegovy) and tirzepatide (Mounjaro) are the two most prescribed GLP-1 based weight loss medications, yet they trigger different patterns of nausea, vomiting, and gastrointestinal distress. Clinical trials show tirzepatide produces greater weight loss but may carry a higher initial side effect burden—though individual responses vary significantly based on genetic factors and dose titration speed.

Nausea and Vomiting: Comparing Wegovy and Mounjaro Side Effects

Nausea is the most commonly reported side effect of both medications, affecting up to 25% of Wegovy users and 35% of Mounjaro users in clinical trials. This difference stems from tirzepatide's dual mechanism: it activates both GLP-1 and GIP receptors, creating a stronger signal to the brain's appetite-control centers. Wegovy, which targets only the GLP-1 receptor, generally produces milder nausea that tends to fade within 2–4 weeks as the body adapts to the medication.

Vomiting occurs in approximately 5–10% of Wegovy patients and 10–15% of Mounjaro patients, particularly during dose escalation. Slower titration schedules—starting at lower doses and increasing gradually over weeks or months—significantly reduce the risk of severe nausea and vomiting. PlexusDx compounded tirzepatide injections allow flexible, personalized dose adjustments that help minimize these gastrointestinal symptoms while maintaining consistent weight loss momentum.

Gastrointestinal Side Effects: Diarrhea, Constipation, and Pancreatitis Risk

Both medications alter gut motility through their effects on glucagon-like peptide-1 signaling, leading to diarrhea or constipation in 20–30% of users. Diarrhea appears more frequently in the first 4–8 weeks, while constipation often emerges during weight loss plateau phases when calorie intake drops sharply. Neither medication causes permanent changes to digestive function, but symptom management through hydration, fiber adjustment, and meal timing substantially improves tolerability.

Pancreatitis—inflammation of the pancreas—is a rare but serious concern, reported in fewer than 1 in 1,000 patients taking either medication. Both GLP-1 and GIP receptor agonists increase amylase and lipase enzymes slightly, but clinical trials show these elevations rarely progress to clinical pancreatitis. Individuals with a personal or family history of pancreatitis should discuss risk factors with a healthcare provider before starting either medication.

Appetite Suppression Intensity and Genetic Predisposition to Side Effects

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Patients carrying certain GLP1R or GIPR variants may experience nausea at lower doses, while others tolerate higher doses with minimal symptoms. Personalized genetic insights allow your healthcare provider to select the optimal starting dose and titration pace, reducing unnecessary side effects without sacrificing efficacy. This precision approach means you spend less time adapting to medication and more time achieving your weight loss goals.

Managing Side Effects and Choosing Between Wegovy and Mounjaro

The 'best' medication depends on your side effect tolerance, weight loss goals, and genetic predisposition to gastrointestinal sensitivity. Wegovy suits patients who prioritize minimal nausea and prefer a gentler introduction to GLP-1 therapy, making it ideal for first-time users or those with sensitive digestion. Mounjaro (tirzepatide) is optimal for patients seeking maximum weight loss and willing to accept temporary nausea during the titration phase in exchange for superior long-term results.

PlexusDx compounds both semaglutide and tirzepatide injections with flexible dosing schedules tailored to your response. Starting at $289/mo for compounded tirzepatide, PlexusDx allows you to adjust your dose without price changes—your dose may need to go up, your price won't. Adding the Precision Peptide Genetic Test ($298) reveals your genetic predisposition to side effects, enabling your provider to craft a truly personalized treatment plan that minimizes nausea while maximizing results.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Mounjaro more likely to cause severe side effects than Wegovy?

Mounjaro triggers nausea and vomiting at slightly higher rates than Wegovy in clinical trials, but most side effects are mild to moderate and resolve within 2–4 weeks. Severe adverse events are rare with both medications. Slow dose titration and personalized dosing schedules—like those available through PlexusDx—substantially reduce side effect intensity while preserving efficacy.

Which medication should I choose if I have a history of nausea?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I switch from Wegovy to Mounjaro if side effects are too severe?

Yes, switching between medications is medically safe and often effective. If Wegovy causes unacceptable side effects, your provider may recommend tirzepatide with a slower titration schedule or lower starting dose. Conversely, if you're not reaching weight loss goals on Wegovy, Mounjaro's dual-receptor mechanism may deliver better results with manageable side effects through personalized dosing.

Does PlexusDx compounded tirzepatide have fewer side effects than brand-name Mounjaro?

PlexusDx tirzepatide is identical in active compound to Mounjaro but sourced from licensed 503A compounding pharmacies and priced at $249/mo regardless of dose. The main advantage is dosing flexibility: your healthcare provider can adjust your dose incrementally to find the sweet spot that maximizes weight loss while minimizing nausea and other side effects—without price escalation.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to Mounjaro or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437) and FTO (rs9939609)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Mounjaro Side Effects Plexusdx
• Mounjaro Side Effects
• Wegovy Side Effects
• Wegovy Vs Mounjaro 2

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.